# CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL

> **NCT03467256** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Federal Research Institute of Pediatric Hematology, Oncology and Immunology** · enrollment: 18 (estimated)

## Conditions studied

- B-cell Acute Lymphoblastic Leukemia
- Acute Lymphocytic Leukemia, Pediatric

## Interventions

- **BIOLOGICAL:** Chimeric Antigen Receptor T-Cell Therapy
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** Tocilizumab
- **DRUG:** Cytarabine
- **DRUG:** Etoposide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT03467256
- **Lead sponsor:** Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-05-14
- **Primary completion:** 2020-10-15
- **Final completion:** 2025-10-15
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2023-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03467256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03467256, "CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03467256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*